Characterisation and outcome of RAC1 mutated melanoma.
Lodde GC, Jansen P, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Sucker A, Placke JM, Zaremba A, Albrecht LJ, Kowall B, Galetzka W, Becker JC, Tasdogan A, Zimmer L, Livingstone E, Hadaschik E, Schadendorf D, Ugurel S, Griewank K.
Lodde GC, et al.
Eur J Cancer. 2023 Apr;183:1-10. doi: 10.1016/j.ejca.2023.01.009. Epub 2023 Jan 18.
Eur J Cancer. 2023.
PMID: 36773463
Objective response rate of first-line treatment in patients with stage III/IV disease was 21%; median overall survival was 47.8 months. CONCLUSIONS: RAC1 mutated melanomas are rare, mostly of cutaneous origin and frequently harbour concomitant MAP kinase mutations, particu …
Objective response rate of first-line treatment in patients with stage III/IV disease was 21%; median overall survival was 47.8 month …